SFTPC and respiratory failure: Here, we described the first report on the successfully repeated administration of intravenously delivered allogeneic BM-MSCs in an infant with a mutation of SFTPC and chronic respiratory failure, supporting that cell therapy could also be considered as a prospective approach to treat congenital respiratory diseases in pediatric populations.